JPRN-UMIN000018788
Completed
Phase 2
Tissue-engineered cultured periosteum used with platelet-rich plasma and hydroxyapatite in treating human osseous defects: second phase of clinical trial. - Clinical effect of cultured periosteal sheet for treating chronic periodontitis.
iigata University0 sites30 target enrollmentAugust 24, 2015
ConditionsChronic periodontitis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Chronic periodontitis
- Sponsor
- iigata University
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Persons who do not accept written informed consent. 2\. Persons not satisfied with a standard of biosafety level 1\. 3\. Persons who had severe systemic complications. 4\. Un\-completion of periodontal initial treatment. 5\. Persons who were unable to accept for periodontal surgery. 6\. Persons who had not one infrabony defect with probing depth: 6mm and more, clinical attachment level: 6mm and more. and osseous defect depth estimated to be 4mm and more radiographically. 7\. Persons who had the allergy due to medication. 8\. Persons who are judged to be unqualified for this study subjects by investigators.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Cultivated epithelial sheet transplantation for corneal epithelial stem cell deficiencya) Steven's Johnson Syndrome b) Ocular cicatricial pemphigoid c) Chemical/ Thermal Burns of the Cornea d) Gelatinous Drop Like Dystrophy e) Salzmann Corneal Degeneration f) Congenital AniridiaJPRN-UMIN000002948Department of Ophthalmology, Keio University School of Medicine5
Active, not recruiting
Phase 1
The aim of this clinical study is to show the clinical efficacy and safety of SMDCs in patients suffering from FI, and to find the optimal cell count for the functional regeneration of the external anal sphincter.Fecal incontinence in female and male patients.MedDRA version: 17.0Level: LLTClassification code 10016296Term: Fecal incontinenceSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2010-021463-32-BGInnovacell Biotechnologie AG252
Active, not recruiting
Phase 1
The aim of this clinical study is to show the clinical efficacy and safety of SMDCs in patients suffering from FI, and to find the optimal cell count for the functional regeneration of the external anal sphincter.Fecal incontinence in female and male patients.MedDRA version: 17.0Level: LLTClassification code 10016296Term: Fecal incontinenceSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2010-021463-32-SIInnovacell Biotechnologie AG252
Active, not recruiting
Phase 1
A clinical trial comparing muscle cell treatment with placebo in fecal incontinence patientsFecal incontinenceMedDRA version: 20.0Level: LLTClassification code 10016296Term: Fecal incontinenceSystem Organ Class: 100000004856MedDRA version: 20.0Level: LLTClassification code 10055507Term: Fecal incontinence aggravatedSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2021-001376-42-ESInnovacell AG290
Active, not recruiting
Phase 1
A clinical trial comparing muscle cell treatment with placebo in fecal incontinence patientsEUCTR2021-001376-42-BGInnovacell AG290